Syndax Says Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis Missed Primary Endpoint, Halts IPF Development
Share
Why It Matters
Syndax tested a new medicine for a lung disease but it did not work as hoped. When a medicine fails a big test, the company often stops that project and investors watch to see what they try next.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.